Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer
Background The discordance of the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expressions between primary cancer and metastatic lesions is an important issue when selecting the optimal treatments for patients with metastatic breast cancer. A rebiopsy for the metastatic...
Gespeichert in:
| Veröffentlicht in: | Breast cancer (Tokyo, Japan) Japan), 2016-07, Vol.23 (4), p.633-639 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 639 |
|---|---|
| container_issue | 4 |
| container_start_page | 633 |
| container_title | Breast cancer (Tokyo, Japan) |
| container_volume | 23 |
| creator | Nakayama, Yuko Nakagomi, Hiroshi Omori, Masato Inoue, Masayuki Takahashi, Kazunori Maruyama, Masahiro Takano, Atsushi Furuya, Kazushige Amemiya, Kenji Ishii, Eri Oyama, Toshio |
| description | Background
The discordance of the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expressions between primary cancer and metastatic lesions is an important issue when selecting the optimal treatments for patients with metastatic breast cancer. A rebiopsy for the metastatic cancer is recommended before selecting the treatment; however, it is not easy to take a tissue sample for all metastatic lesions. Fine needle aspiration cytology (FNA) for regional lymph nodes and aspiration for pleural effusions or ascites are less invasive procedures to obtain the necessary samples to examine the HR/HER2 expression. These cytologic materials are able to be stained as a tissue sample using the cell block method.
Patients
We examined the HR/HER2 expression of 20 patients with breast cancer (8 with synchronous metastases and 12 with metachronous metastases) using the cell block method. Among 8 patients with synchronous metastases, 7 patients with axillary lymph node (LN) metastasis were examined by fine needle aspiration (FNA), and one patient with pleural metastases was analyzed for the aspirated fluid. While in 12 patients with metachronous metastases, 7 patients were examined for their pleural effusion, 3 patients were examined for regional lymph node metastases, and 1 patient were examined for aspirated ascites. We compared the HR/HER expression between primary cancer and metastatic lesion in 17 patients (5 cases of 8 synchronous metastases, and all of 12 metachronous metastases).
Results
Discordance of HR was seen in 4 of 17 patients (24 %). Three cases with axillary LN metastasis (2 cases with synchronous metastases and one with metachronous metastasis) showed negative change of ER. Negative change of HER2 expression was seen in one patient with ascites caused by peritoneal dissemination.
Conclusions
Cytology materials are easily obtained by FNA for LN metastases and aspiration for malignant effusions and analyzed for HR/HER2 expression using cell block method. We should take advantage of cell block analysis to determine the discordance of the HR/HER2 expression to select the optimal treatment for metastatic breast cancer. |
| doi_str_mv | 10.1007/s12282-015-0615-x |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1797873016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712277218</galeid><sourcerecordid>A712277218</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-2f2bbc27c7a8454501b044ed72269860c9653d604e20c24c7a573eca1e0084a43</originalsourceid><addsrcrecordid>eNp9kduKFDEQhoMo7kEfwBsJeONN7-bUSeZyXdYdYUFY9Dqk09UzWbuTMUnj-AY-tml7FQSRQFJUvr-Sqh-hV5RcUELUZaaMadYQ2jZE1u34BJ1SrUkjGOdPa8wFaaSW-gSd5fxAiOCKyOfohLUbqbnQp-jHOwgw-JJxHPCcfdjhsgfsYBxxN0b3BU9Q9rHHJeIeCqTJB_iF9D67mHobHCzaJbW9v9ze3DMMx0OCnH0M2Ad8sMVDqC9882W_lLO51JTDXYIaYreUSC_Qs8GOGV4-nufo8_ubT9fb5u7j7Yfrq7vGCd6Whg2s6xxTTlktWtES2hEhoFeMyY2WxG1ky3tJBDDimKhYqzg4S4EQLazg5-jtWveQ4tcZcjFTbaS2awPEORuqNkorTqis6JsV3dkRjA9DLMm6BTdXqo5eKUZ1pS7-QdXVw-RdXKZb838J6CpwKeacYDCH5CebvhtKzOKrWX011Vez-GqOVfP68ddzN0H_R_HbyAqwFcj1KuwgmYc4p1An-Z-qPwF3jK0k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797873016</pqid></control><display><type>article</type><title>Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Nakayama, Yuko ; Nakagomi, Hiroshi ; Omori, Masato ; Inoue, Masayuki ; Takahashi, Kazunori ; Maruyama, Masahiro ; Takano, Atsushi ; Furuya, Kazushige ; Amemiya, Kenji ; Ishii, Eri ; Oyama, Toshio</creator><creatorcontrib>Nakayama, Yuko ; Nakagomi, Hiroshi ; Omori, Masato ; Inoue, Masayuki ; Takahashi, Kazunori ; Maruyama, Masahiro ; Takano, Atsushi ; Furuya, Kazushige ; Amemiya, Kenji ; Ishii, Eri ; Oyama, Toshio</creatorcontrib><description>Background
The discordance of the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expressions between primary cancer and metastatic lesions is an important issue when selecting the optimal treatments for patients with metastatic breast cancer. A rebiopsy for the metastatic cancer is recommended before selecting the treatment; however, it is not easy to take a tissue sample for all metastatic lesions. Fine needle aspiration cytology (FNA) for regional lymph nodes and aspiration for pleural effusions or ascites are less invasive procedures to obtain the necessary samples to examine the HR/HER2 expression. These cytologic materials are able to be stained as a tissue sample using the cell block method.
Patients
We examined the HR/HER2 expression of 20 patients with breast cancer (8 with synchronous metastases and 12 with metachronous metastases) using the cell block method. Among 8 patients with synchronous metastases, 7 patients with axillary lymph node (LN) metastasis were examined by fine needle aspiration (FNA), and one patient with pleural metastases was analyzed for the aspirated fluid. While in 12 patients with metachronous metastases, 7 patients were examined for their pleural effusion, 3 patients were examined for regional lymph node metastases, and 1 patient were examined for aspirated ascites. We compared the HR/HER expression between primary cancer and metastatic lesion in 17 patients (5 cases of 8 synchronous metastases, and all of 12 metachronous metastases).
Results
Discordance of HR was seen in 4 of 17 patients (24 %). Three cases with axillary LN metastasis (2 cases with synchronous metastases and one with metachronous metastasis) showed negative change of ER. Negative change of HER2 expression was seen in one patient with ascites caused by peritoneal dissemination.
Conclusions
Cytology materials are easily obtained by FNA for LN metastases and aspiration for malignant effusions and analyzed for HR/HER2 expression using cell block method. We should take advantage of cell block analysis to determine the discordance of the HR/HER2 expression to select the optimal treatment for metastatic breast cancer.</description><identifier>ISSN: 1340-6868</identifier><identifier>EISSN: 1880-4233</identifier><identifier>DOI: 10.1007/s12282-015-0615-x</identifier><identifier>PMID: 25968348</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis ; Biopsy, Fine-Needle - methods ; Breast cancer ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cancer Research ; Care and treatment ; Cytodiagnosis - methods ; Epidermal growth factor ; Female ; Humans ; Lymphatic Metastasis - pathology ; Medicine ; Medicine & Public Health ; Metastasis ; Methods ; Middle Aged ; Oncology ; Original Article ; Receptor, ErbB-2 - analysis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - analysis ; Receptors, Estrogen - metabolism ; Reproducibility of Results ; Surgery ; Surgical Oncology</subject><ispartof>Breast cancer (Tokyo, Japan), 2016-07, Vol.23 (4), p.633-639</ispartof><rights>The Japanese Breast Cancer Society 2015</rights><rights>COPYRIGHT 2016 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-2f2bbc27c7a8454501b044ed72269860c9653d604e20c24c7a573eca1e0084a43</citedby><cites>FETCH-LOGICAL-c435t-2f2bbc27c7a8454501b044ed72269860c9653d604e20c24c7a573eca1e0084a43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12282-015-0615-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12282-015-0615-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25968348$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakayama, Yuko</creatorcontrib><creatorcontrib>Nakagomi, Hiroshi</creatorcontrib><creatorcontrib>Omori, Masato</creatorcontrib><creatorcontrib>Inoue, Masayuki</creatorcontrib><creatorcontrib>Takahashi, Kazunori</creatorcontrib><creatorcontrib>Maruyama, Masahiro</creatorcontrib><creatorcontrib>Takano, Atsushi</creatorcontrib><creatorcontrib>Furuya, Kazushige</creatorcontrib><creatorcontrib>Amemiya, Kenji</creatorcontrib><creatorcontrib>Ishii, Eri</creatorcontrib><creatorcontrib>Oyama, Toshio</creatorcontrib><title>Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer</title><title>Breast cancer (Tokyo, Japan)</title><addtitle>Breast Cancer</addtitle><addtitle>Breast Cancer</addtitle><description>Background
The discordance of the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expressions between primary cancer and metastatic lesions is an important issue when selecting the optimal treatments for patients with metastatic breast cancer. A rebiopsy for the metastatic cancer is recommended before selecting the treatment; however, it is not easy to take a tissue sample for all metastatic lesions. Fine needle aspiration cytology (FNA) for regional lymph nodes and aspiration for pleural effusions or ascites are less invasive procedures to obtain the necessary samples to examine the HR/HER2 expression. These cytologic materials are able to be stained as a tissue sample using the cell block method.
Patients
We examined the HR/HER2 expression of 20 patients with breast cancer (8 with synchronous metastases and 12 with metachronous metastases) using the cell block method. Among 8 patients with synchronous metastases, 7 patients with axillary lymph node (LN) metastasis were examined by fine needle aspiration (FNA), and one patient with pleural metastases was analyzed for the aspirated fluid. While in 12 patients with metachronous metastases, 7 patients were examined for their pleural effusion, 3 patients were examined for regional lymph node metastases, and 1 patient were examined for aspirated ascites. We compared the HR/HER expression between primary cancer and metastatic lesion in 17 patients (5 cases of 8 synchronous metastases, and all of 12 metachronous metastases).
Results
Discordance of HR was seen in 4 of 17 patients (24 %). Three cases with axillary LN metastasis (2 cases with synchronous metastases and one with metachronous metastasis) showed negative change of ER. Negative change of HER2 expression was seen in one patient with ascites caused by peritoneal dissemination.
Conclusions
Cytology materials are easily obtained by FNA for LN metastases and aspiration for malignant effusions and analyzed for HR/HER2 expression using cell block method. We should take advantage of cell block analysis to determine the discordance of the HR/HER2 expression to select the optimal treatment for metastatic breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Biopsy, Fine-Needle - methods</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Cytodiagnosis - methods</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphatic Metastasis - pathology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - analysis</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Reproducibility of Results</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><issn>1340-6868</issn><issn>1880-4233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kduKFDEQhoMo7kEfwBsJeONN7-bUSeZyXdYdYUFY9Dqk09UzWbuTMUnj-AY-tml7FQSRQFJUvr-Sqh-hV5RcUELUZaaMadYQ2jZE1u34BJ1SrUkjGOdPa8wFaaSW-gSd5fxAiOCKyOfohLUbqbnQp-jHOwgw-JJxHPCcfdjhsgfsYBxxN0b3BU9Q9rHHJeIeCqTJB_iF9D67mHobHCzaJbW9v9ze3DMMx0OCnH0M2Ad8sMVDqC9882W_lLO51JTDXYIaYreUSC_Qs8GOGV4-nufo8_ubT9fb5u7j7Yfrq7vGCd6Whg2s6xxTTlktWtES2hEhoFeMyY2WxG1ky3tJBDDimKhYqzg4S4EQLazg5-jtWveQ4tcZcjFTbaS2awPEORuqNkorTqis6JsV3dkRjA9DLMm6BTdXqo5eKUZ1pS7-QdXVw-RdXKZb838J6CpwKeacYDCH5CebvhtKzOKrWX011Vez-GqOVfP68ddzN0H_R_HbyAqwFcj1KuwgmYc4p1An-Z-qPwF3jK0k</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Nakayama, Yuko</creator><creator>Nakagomi, Hiroshi</creator><creator>Omori, Masato</creator><creator>Inoue, Masayuki</creator><creator>Takahashi, Kazunori</creator><creator>Maruyama, Masahiro</creator><creator>Takano, Atsushi</creator><creator>Furuya, Kazushige</creator><creator>Amemiya, Kenji</creator><creator>Ishii, Eri</creator><creator>Oyama, Toshio</creator><general>Springer Japan</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160701</creationdate><title>Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer</title><author>Nakayama, Yuko ; Nakagomi, Hiroshi ; Omori, Masato ; Inoue, Masayuki ; Takahashi, Kazunori ; Maruyama, Masahiro ; Takano, Atsushi ; Furuya, Kazushige ; Amemiya, Kenji ; Ishii, Eri ; Oyama, Toshio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-2f2bbc27c7a8454501b044ed72269860c9653d604e20c24c7a573eca1e0084a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Biopsy, Fine-Needle - methods</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Cytodiagnosis - methods</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphatic Metastasis - pathology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - analysis</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Reproducibility of Results</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakayama, Yuko</creatorcontrib><creatorcontrib>Nakagomi, Hiroshi</creatorcontrib><creatorcontrib>Omori, Masato</creatorcontrib><creatorcontrib>Inoue, Masayuki</creatorcontrib><creatorcontrib>Takahashi, Kazunori</creatorcontrib><creatorcontrib>Maruyama, Masahiro</creatorcontrib><creatorcontrib>Takano, Atsushi</creatorcontrib><creatorcontrib>Furuya, Kazushige</creatorcontrib><creatorcontrib>Amemiya, Kenji</creatorcontrib><creatorcontrib>Ishii, Eri</creatorcontrib><creatorcontrib>Oyama, Toshio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakayama, Yuko</au><au>Nakagomi, Hiroshi</au><au>Omori, Masato</au><au>Inoue, Masayuki</au><au>Takahashi, Kazunori</au><au>Maruyama, Masahiro</au><au>Takano, Atsushi</au><au>Furuya, Kazushige</au><au>Amemiya, Kenji</au><au>Ishii, Eri</au><au>Oyama, Toshio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer</atitle><jtitle>Breast cancer (Tokyo, Japan)</jtitle><stitle>Breast Cancer</stitle><addtitle>Breast Cancer</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>23</volume><issue>4</issue><spage>633</spage><epage>639</epage><pages>633-639</pages><issn>1340-6868</issn><eissn>1880-4233</eissn><abstract>Background
The discordance of the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expressions between primary cancer and metastatic lesions is an important issue when selecting the optimal treatments for patients with metastatic breast cancer. A rebiopsy for the metastatic cancer is recommended before selecting the treatment; however, it is not easy to take a tissue sample for all metastatic lesions. Fine needle aspiration cytology (FNA) for regional lymph nodes and aspiration for pleural effusions or ascites are less invasive procedures to obtain the necessary samples to examine the HR/HER2 expression. These cytologic materials are able to be stained as a tissue sample using the cell block method.
Patients
We examined the HR/HER2 expression of 20 patients with breast cancer (8 with synchronous metastases and 12 with metachronous metastases) using the cell block method. Among 8 patients with synchronous metastases, 7 patients with axillary lymph node (LN) metastasis were examined by fine needle aspiration (FNA), and one patient with pleural metastases was analyzed for the aspirated fluid. While in 12 patients with metachronous metastases, 7 patients were examined for their pleural effusion, 3 patients were examined for regional lymph node metastases, and 1 patient were examined for aspirated ascites. We compared the HR/HER expression between primary cancer and metastatic lesion in 17 patients (5 cases of 8 synchronous metastases, and all of 12 metachronous metastases).
Results
Discordance of HR was seen in 4 of 17 patients (24 %). Three cases with axillary LN metastasis (2 cases with synchronous metastases and one with metachronous metastasis) showed negative change of ER. Negative change of HER2 expression was seen in one patient with ascites caused by peritoneal dissemination.
Conclusions
Cytology materials are easily obtained by FNA for LN metastases and aspiration for malignant effusions and analyzed for HR/HER2 expression using cell block method. We should take advantage of cell block analysis to determine the discordance of the HR/HER2 expression to select the optimal treatment for metastatic breast cancer.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>25968348</pmid><doi>10.1007/s12282-015-0615-x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-6868 |
| ispartof | Breast cancer (Tokyo, Japan), 2016-07, Vol.23 (4), p.633-639 |
| issn | 1340-6868 1880-4233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1797873016 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Aged, 80 and over Analysis Biopsy, Fine-Needle - methods Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer Research Care and treatment Cytodiagnosis - methods Epidermal growth factor Female Humans Lymphatic Metastasis - pathology Medicine Medicine & Public Health Metastasis Methods Middle Aged Oncology Original Article Receptor, ErbB-2 - analysis Receptor, ErbB-2 - metabolism Receptors, Estrogen - analysis Receptors, Estrogen - metabolism Reproducibility of Results Surgery Surgical Oncology |
| title | Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T21%3A07%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benefits%20of%20using%20the%20cell%20block%20method%20to%20determine%20the%20discordance%20of%20the%20HR/HER2%20expression%20in%20patients%20with%20metastatic%20breast%20cancer&rft.jtitle=Breast%20cancer%20(Tokyo,%20Japan)&rft.au=Nakayama,%20Yuko&rft.date=2016-07-01&rft.volume=23&rft.issue=4&rft.spage=633&rft.epage=639&rft.pages=633-639&rft.issn=1340-6868&rft.eissn=1880-4233&rft_id=info:doi/10.1007/s12282-015-0615-x&rft_dat=%3Cgale_proqu%3EA712277218%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1797873016&rft_id=info:pmid/25968348&rft_galeid=A712277218&rfr_iscdi=true |